Recent Searches
Trending
-
Why a level head is needed to deal with geopolitical risk
23 Aug 2023 Geostrategy -
How do CEOs reimagine enterprises for a future that keeps rewriting itself?
20 Jan 2026 CEO agenda -
Why net-zero supply chains are the next big opportunity for business
02 Aug 2021 Climate change and sustainability services
Life Sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
Our latest thinking
How next-generation CRM will reshape the life sciences commercial model
CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.
EY Biotech Beyond Borders Report 2026
Biotech companies and life sciences leaders are seeking a balanced path forward between major opportunities and significant challenges. Find out how.
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed. Read more.
EY Pulse of the MedTech Industry Report 2026
The 20th edition of the EY Pulse of the MedTech Industry captures the medical devices sector at both a high point and a turning point. Find out how.
What pharma supply chain transformation means for tax
Businesses looking to create visibility and resilience in their supply chains must loop in tax and transfer pricing teams early in the process. Learn more.
How life sciences can make the right deals in a time of change
Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.
How will you respond to clinicians sounding the alarm on unsustainable care delivery models?
The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.
Why digital supply chain visibility should be a pharma priority
With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.
How digital is changing the tax strategy for MedTech
As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.
How Takeda accelerated the financial close process by nearly two weeks
In this case study, learn how leading pharmaceutical company Takeda is creating value for patients through finance innovation and process excellence.
How early diagnosis can transform health care
Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.
How innovation can unlock the power of data to deliver value-based care
Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
Why life sciences tax departments need to act now on sustainability
Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.
How do you build future supply chains to best serve patient needs?
In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.
How CDMOs are leading innovation for pharmaceutical partners
Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.
What going digital means for Takeda
Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.
How to navigate global transfer pricing controversy in life sciences
Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.
How you can create value in an intelligent health ecosystem
The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.
How to navigate EU regulations for drug-device combination products
The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.
How one entrepreneur seeks to make affordable health care a reality
Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.
How ecosystem participation drives more value for life sciences deals
Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
How the future of health care is becoming a reality
Human-centric care will soon become a reality, driven by data and technology.
Five trends redefining the health sciences and wellness operating model
As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.
Optimizing health outcomes for all
Discover key insights that highlight strategic priorities and investments to enhance care across sectors, along with the evolution of organizational capabilities, based on a survey of 500 industry leaders.
How AI can support decision-making in drug development portfolios
For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.
How EY can help
-
The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more -
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more -
Read more
-
Our Healthcare Strategy Consulting teams help organizations develop digital, transaction and value strategies to build resilience and drive future growth
Read more
Direct to your inbox
Stay up to date with our Editor's picks newsletter.
Case studies
How IntraBio's finance transformation fueled its global expansion
For its global expansion, IntraBio needed to solve operational and financial back-office challenges. Learn how EY finance transformation services helped.
How tech and trust transformed a tax operating model
Global pharmaceutical player Boehringer Ingelheim is reimaging its tax operating model to boost quality and efficiency. Learn more in this case study.
How a global biopharma became a leader in ethical AI
Read this case study about how a science-led biopharma positioned itself as a leader in ethical AI.
